Merck Says KEYTRUDA Reduced Progression or Death Risk by 43% in Endometrial Cancer Trial
Merck said first results from its Phase 3 KEYNOTE-C93 trial found KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% versus chemotherapy in certain patients with advanced or recurrent endometrial cancer and dMMR tumors.
Story updates
03:35:28 PM UTC
SquawkNews
KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these